Cargando…

局部晚期中央型肺癌化疗联合免疫新辅助治疗后机器人辅助支气管袖状切除的安全性与可行性

BACKGROUND AND OBJECTIVE: Immunoneoadjuvant therapy opens a new prospect for local advanced lung cancer. The aim of our study was to explore the safety and feasibility of robotic-assisted bronchial sleeve resection in patients with locally advanced non-small cell lung cancer (NSCLC) after neoadjuvan...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913288/
https://www.ncbi.nlm.nih.gov/pubmed/35224959
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.46
_version_ 1784667403225923584
collection PubMed
description BACKGROUND AND OBJECTIVE: Immunoneoadjuvant therapy opens a new prospect for local advanced lung cancer. The aim of our study was to explore the safety and feasibility of robotic-assisted bronchial sleeve resection in patients with locally advanced non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy. METHODS: Data of 13 patients with locally advanced NSCLC that underwent bronchial sleeve resection after neoadjuvant chemoimmunotherapy during August 2020 and February 2021 were retrospectively included. According to the surgical methods, patients were divided into thoracotomy bronchial sleeve resection (TBSR) group and robot-assisted bronchial sleeve resection (RABSR) group. Oncology, intraoperative, and postoperative data in the two groups were compared. RESULTS: The two groups of patients operated smoothly, the postoperative pathology confirmed that all the tumor lesions achieved R0 resection, and RABSR group no patient was transferred to thoracotomy during surgery. Partial remission (PR) rate and major pathological remissions (MPR) rate of patients in the TBSR group were 71.43% and 42.86%, respectively. Complete pathological response (pCR) was 28.57%. They were 66.67%, 50.00% and 33.33% in RABSR group, respectively. There were no significant differences in operative duration, number of lymph nodes dissected, intraoperative blood loss, postoperative drainage time and postoperative hospital stay between the two groups, but the bronchial anastomosis time of RABSR group was relatively short. Both groups of patients had a good prognosis. Successfully discharged from the hospital and post-operative 90-d mortality rate was 0. CONCLUSION: In patients with locally advanced central NSCLC after neoadjuvant chemoimmunotherapy can achieve the tumor reduction, tumor stage decline and increase the R0 resection rate, bronchial sleeve resection is safe and feasible. Under the premise of following the two principles of surgical safety and realizing the tumor R0 resection, robot-assisted bronchial sleeve resection can be preferred.
format Online
Article
Text
id pubmed-8913288
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-89132882022-03-25 局部晚期中央型肺癌化疗联合免疫新辅助治疗后机器人辅助支气管袖状切除的安全性与可行性 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Immunoneoadjuvant therapy opens a new prospect for local advanced lung cancer. The aim of our study was to explore the safety and feasibility of robotic-assisted bronchial sleeve resection in patients with locally advanced non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy. METHODS: Data of 13 patients with locally advanced NSCLC that underwent bronchial sleeve resection after neoadjuvant chemoimmunotherapy during August 2020 and February 2021 were retrospectively included. According to the surgical methods, patients were divided into thoracotomy bronchial sleeve resection (TBSR) group and robot-assisted bronchial sleeve resection (RABSR) group. Oncology, intraoperative, and postoperative data in the two groups were compared. RESULTS: The two groups of patients operated smoothly, the postoperative pathology confirmed that all the tumor lesions achieved R0 resection, and RABSR group no patient was transferred to thoracotomy during surgery. Partial remission (PR) rate and major pathological remissions (MPR) rate of patients in the TBSR group were 71.43% and 42.86%, respectively. Complete pathological response (pCR) was 28.57%. They were 66.67%, 50.00% and 33.33% in RABSR group, respectively. There were no significant differences in operative duration, number of lymph nodes dissected, intraoperative blood loss, postoperative drainage time and postoperative hospital stay between the two groups, but the bronchial anastomosis time of RABSR group was relatively short. Both groups of patients had a good prognosis. Successfully discharged from the hospital and post-operative 90-d mortality rate was 0. CONCLUSION: In patients with locally advanced central NSCLC after neoadjuvant chemoimmunotherapy can achieve the tumor reduction, tumor stage decline and increase the R0 resection rate, bronchial sleeve resection is safe and feasible. Under the premise of following the two principles of surgical safety and realizing the tumor R0 resection, robot-assisted bronchial sleeve resection can be preferred. 中国肺癌杂志编辑部 2022-02-20 /pmc/articles/PMC8913288/ /pubmed/35224959 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.46 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 临床研究
局部晚期中央型肺癌化疗联合免疫新辅助治疗后机器人辅助支气管袖状切除的安全性与可行性
title 局部晚期中央型肺癌化疗联合免疫新辅助治疗后机器人辅助支气管袖状切除的安全性与可行性
title_full 局部晚期中央型肺癌化疗联合免疫新辅助治疗后机器人辅助支气管袖状切除的安全性与可行性
title_fullStr 局部晚期中央型肺癌化疗联合免疫新辅助治疗后机器人辅助支气管袖状切除的安全性与可行性
title_full_unstemmed 局部晚期中央型肺癌化疗联合免疫新辅助治疗后机器人辅助支气管袖状切除的安全性与可行性
title_short 局部晚期中央型肺癌化疗联合免疫新辅助治疗后机器人辅助支气管袖状切除的安全性与可行性
title_sort 局部晚期中央型肺癌化疗联合免疫新辅助治疗后机器人辅助支气管袖状切除的安全性与可行性
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913288/
https://www.ncbi.nlm.nih.gov/pubmed/35224959
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.46
work_keys_str_mv AT júbùwǎnqīzhōngyāngxíngfèiáihuàliáoliánhémiǎnyìxīnfǔzhùzhìliáohòujīqìrénfǔzhùzhīqìguǎnxiùzhuàngqièchúdeānquánxìngyǔkěxíngxìng
AT júbùwǎnqīzhōngyāngxíngfèiáihuàliáoliánhémiǎnyìxīnfǔzhùzhìliáohòujīqìrénfǔzhùzhīqìguǎnxiùzhuàngqièchúdeānquánxìngyǔkěxíngxìng
AT júbùwǎnqīzhōngyāngxíngfèiáihuàliáoliánhémiǎnyìxīnfǔzhùzhìliáohòujīqìrénfǔzhùzhīqìguǎnxiùzhuàngqièchúdeānquánxìngyǔkěxíngxìng
AT júbùwǎnqīzhōngyāngxíngfèiáihuàliáoliánhémiǎnyìxīnfǔzhùzhìliáohòujīqìrénfǔzhùzhīqìguǎnxiùzhuàngqièchúdeānquánxìngyǔkěxíngxìng
AT júbùwǎnqīzhōngyāngxíngfèiáihuàliáoliánhémiǎnyìxīnfǔzhùzhìliáohòujīqìrénfǔzhùzhīqìguǎnxiùzhuàngqièchúdeānquánxìngyǔkěxíngxìng